CDER Conversations
CDER Conversation: OGD Global Affairs Program, One Year Progress Report of Generic Drug Cluster
Through a rigorous scientific and regulatory process, CDER’s Office of Generic Drugs (OGD) helps to ensure Americans have access to safe, effective, and high-quality generic drugs. The role of the Global Generic Drug Affairs Program is to lead, coordinate, and manage OGD’s international activities in collaboration with other offices in CDER offices and throughout the FDA to advance the overall mission of OGD and FDA. In an increasingly globalized pharmaceutical market, collaboration among drug regulators is critical. Actions one country or territory takes can affect others.
In this CDER Conversation, we reflect on the first-year progress of the Generic Drug Cluster with OGD’s Sarah Ibrahim PhD., associate director for Global Generic Drug Affairs.